A concentrated spice extract taken at about 30 milligrams daily. Its best-supported effect is on low mood, roughly level with standard antidepressant medication, with fewer unwanted effects. Smaller, less certain signals cover sleep, thinking, blood sugar, blood pressure, sexual function, and central vision. Almost all findings come from people who already had the problem, so a healthy adult is extrapolating. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting blood glucose | 75–86 mg/dL | Detects the glucose shift saffron produces and flags additive lows |
| HbA1c | 4.8–5.3% | Confirms whether the glucose change is sustained rather than a single-day artefact |
| Blood pressure, seated and standing | Under 120/80 mmHg seated, less than a 10 mmHg systolic fall on standing | Saffron lowers pressure modestly; the standing value exposes orthostatic hypotension |
| Hemoglobin and hematocrit | Hemoglobin 13.5–15.0 g/dL in men, 12.5–14.5 g/dL in women | High-dose saffron lowered red cell indices in a controlled safety study |
| Platelet count | 175–250 ×10⁹/L | Tracks the platelet-lowering signal that underlies the bleeding concern |
| ALT and AST | ALT 10–19 U/L in women, 10–26 U/L in men; AST 10–26 U/L | Saffron slightly lowers ALT, so a rise points to another cause |
| Serum creatinine with eGFR | Creatinine 0.7–1.1 mg/dL in men, 0.6–0.9 mg/dL in women; eGFR above 90 mL/min/1.73 m² | Crocin-containing products have been associated with small creatinine rises |
| High-sensitivity C-reactive protein | Under 1.0 mg/L | Identifies who is likely to see any inflammatory benefit at all |
| Mood, anxiety, and sleep questionnaire scores | No established laboratory target; track change from personal baseline, with a 7-point fall on a 21-item depression, anxiety and stress scale treated as meaningful | This is the outcome saffron is actually taken for |
| Best-corrected visual acuity and contrast sensitivity | No established target; track change from personal baseline | Relevant only where early macular degeneration is already present |
Cadence: Baseline before the first dose; questionnaires repeated at 4, 8, and 12 weeks; blood pressure rechecked at 2 and 8 weeks; bloods repeated at 12 weeks, then every 6 to 12 months on continued use, with an additional blood count at 12 weeks wherever daily intake exceeds 30 mg